Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
The present specification relates to a composition containing a peptide having effects of increasing telomerase activity and extending a telomere, and more specifically, to a composition containing a telomerase-derived peptide, thereby being effective for preventing, alleviating and treating diseases, caused by a decrease in telomerase activity or a reduction in telomere length, and symptoms caused by cell aging or damage. According to one aspect to the present invention, the peptide increases telomerase activity and is effective for extending a telomere, and thus a method for treating diseases induced by an abnormal decrease in telomerase activity and by the length reduction or loss of a telomere and alleviating symptoms caused thereby can be provided.
1. A method of increasing telomerase activity or extending a telomere length in a patient suffering from a disease caused by a decrease in telomerase activity or telomere length or a symptom caused by cell loss and senescence comprising administering to the patient a composition comprising the isolated peptide of SEQ ID NO: 1 by injection, wherein the disease is one or more selected from a neurodegenerative disorder, a degenerative disease of the nervous system, a degenerative disease of the skeletal system, a degenerative disease of the muscular system, a viral infectious disease, and a genetic disease causing accelerated cell mortality, wherein the degenerative disease of the nervous system is one or more selected from a brain disease, a peripheral nerve injury, a peripheral nerve disease, amyotrophic lateral sclerosis, dementia, Huntington's disease, Parkinson's disease, spinal cord cerebellar degeneration, and multiple neuropathy, wherein the symptom caused by cell loss and senescence include one or more selected from tissue loss caused by skin wounds, skin wrinkles, anemia, and skin darkening.
2. The method according to claim 1 , wherein the peptide of SEQ ID NO: 1 is administered at a daily dose of 0.1 μg/kg to 10 g/kg.
3. The method according to claim 1 , wherein the peptide of SEQ ID NO: 1 is administered at a daily dose of 0.5 μg/kg to 100 mg/kg.
4. The method according to claim 1 , wherein the composition is administered 1 to 3 times per day.
5. The method according to claim 1 , wherein the composition is a pharmaceutical composition.
6. The method according to claim 1 , wherein the composition is administered through intravenous, intramuscular, or subcutaneous route.